https://ph-ksp.com/the-pulmonary-vascular-research-institute-pvri-publishes-a-13-part-series-to-help-people-living-with-pulmonary-hypertension-ph-their-families-and-carers-understand-clinical-trials/ 2026-08-28T15:15:25Z PULMONARY HYPERTENSION en The Pulmonary Vascular Research Institute (PVRI) publishes a 13-part series to help people living with pulmonary hypertension (PH), their families, and carers understand clinical trials, 2026-08-28T15:15:23Z Blog https://ph-ksp.com/long-term-efficacy-and-safety-of-rehabilitation-in-patients-with-pulmonary-arterial-hypertension-the-fonce-htap-randomized-controlled-trial-annals-of-the-american-thoracic-society-july-20-2026/ 2026-08-28T15:07:11Z PULMONARY HYPERTENSION en Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial, Annals of the American Thoracic Society, July 20, 2026 2026-08-28T15:05:11Z Blog https://ph-ksp.com/predictive-power-of-pulmonary-artery-stiffness-right-ventricular-interplay-but-not-pulmonary-vascular-resistance-in-mild-pulmonary-hypertension-a-pvri-godeep-meta-registry-analysis-chest-august/ 2026-08-28T14:45:36Z PULMONARY HYPERTENSION en Predictive Power of Pulmonary Artery Stiffness - Right Ventricular Interplay, but not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension: A PVRI GoDeep meta-registry analysis, CHEST, August 26, 2026 2026-08-28T14:45:33Z Blog https://ph-ksp.com/us-food-and-drug-administration-fda-accepts-for-review-a-new-drug-application-nda-for-ralinepag-an-investigational-prostacyclin-ip-receptor-agonist-to-treat-pulmonary-arterial-hypertension/ 2026-08-28T14:35:34Z PULMONARY HYPERTENSION en US Food and Drug Administration (FDA) accepts for review a New Drug Application (NDA) for ralinepag, an investigational prostacyclin IP receptor agonist to treat pulmonary arterial hypertension (PAH), Biospace, August 24, 2026 2026-08-28T14:35:33Z Blog